Related Experiment Video
Updated: Jul 5, 2026

Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
Critical update and emerging trends in imatinib treatment for gastrointestinal stromal tumor
Ugo De Giorgi1, Alberto Pupi, Gina Turrisi
1Istituto Toscano Tumori-Department of Oncology, San Giuseppe Hospital, Empoli. ugo_degiorgi@yahoo.com
Abstract:
The extraordinary success of imatinib in gastrointestinal stromal tumor (GIST) represents a model for molecularly targeted therapy of solid tumors. Research is currently going to identify the molecular basis of mechanisms of action and drug resistance. For the optimal management of the patients treated, a multidisciplinary approach, including medical oncologists, surgeons, pathologists, and radiologists is needed. In this article, we reviewed recent advances in the clinical management of GIST patients treated with imatinib, and in the knowledge of the molecular mechanisms that are basic to imatinib effects.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Drugs that Stabilize Microtubules
Treatment Resistent Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers
